DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for acrocephalosyndactyly — screening already-approved drugs against its 28-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAcrocephalosyndactyly maps to a 28-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for acrocephalosyndactyly is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fibroblast growth factor 2 (FGF2) — FGF2 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet idydrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4OEE · 1.5 Å · ligand 1-O-methyl-2-O-sulfo-alpha-L-idopyranuronic acid (IDY). Experimental structure, not a prediction.
What the evidence adds up to
The 1977 family study identified two different acrocephalosyndactyly (ACS) phenotypes—Pfeiffer syndrome in the proband and Apert syndrome in her cousin—within a single kindred. Seven additional family members had unusually shaped heads and facial features reminiscent of Crouzon disease. The authors concluded from this family and previous reports that the Apert and Pfeiffer types of ACS may be one and the same, and called for a re-evaluation of the ACS classification. A 1953 case report described a single patient with Apert syndrome, noting the high degree of function the patient developed in grossly deformed hands and feet; that case showed no evidence of being familial, and the author classified the condition among skull deformities arising from an inherent defect of the germ plasm.
A 1978 linkage analysis was performed on the same 1977 family, which showed multiple cases of dominantly inherited ACS across multiple generations. The analysis required the trait to be monogenic, and the authors considered this prerequisite presumptively established in that single kindred. No specific gene or chromosomal locus was identified in any of these three papers, and no treatment or intervention was tested or discussed.
What is missing is any molecular genetic characterisation of the condition, any animal model, any drug screen, and any clinical trial. No patient stratification beyond crude syndromic labels exists in these reports, and no funding for a repurposing study has been described.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 1977 · 26 citations
On the classification of the acrocephalosyndactyly syndromes
AbstractThis report describes a family in which two different types of acrocephalosyndactyly (ACS) were clinically identified. The proband presented with the classic stigmata of Pfeiffer syndrome, while her cousin was considered to be a typical case of Apert syndrome. Seven other family members also have unusually shaped heads and the facial appearance reminiscent of Crouzon disease. From the observations made in this family and from previous reports in the literature, we feel there is substantial reason to re-evaluate the ACS classification and to consider that the Apert and Pfeiffer types of ACS may be one and the same.
AbstractA case of Acrocephalosyndactyly, as first described by Apert, is reported. Reference is made to the high degree of function developed by the patient in grossly deformed hands and feet. There is no evidence that this case is familial and a review and discussion of some of the literature indicates that the condition belongs to the group of skull deformities resulting from an inherent defect of the germ plasm. A classification of these is suggested.
Journal of Medical Genetics · 1978 · 6 citations · open access
Linkage analysis in dominant acrocephalosyndactyly.
AbstractLinkage analysis was performed on a previously reported family in which multiple dominantly inherited acrocephalosyndactyly syndromes were present. An underlying axiom of linkaged analysis is that the trait analysed be monogenic. This prerequisite was presumptively established in the single kindred analysed because acrocephalosyndactyly was observed in multiple cases in multiple generations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
